NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NextPoint Therapeutics

NextPoint Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://nextpointtx.com/

Last Round

Series B

Extension

Feb 14, 2024

Total Funding Raised

$196M

Company Overview

NextPoint Therapeutics is a biotechnology company developing precision immuno-oncology therapeutics that target the B7-H7/HHLA2 immune checkpoint axis to treat solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyHHLA2monoclonal antibodyimmune checkpointbiotech startupcancer immunotherapyclinical-stage biotechdrug developmentantibody-drug conjugateADCT-cell engagerbiopharmaclinical trialsimmune evasionbiologics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NextPoint Therapeutics Comps

Public and private peers based on sector, stage, and business model.

NextPoint Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

NextPoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 14, 2024
Series BJan 10, 2023
Series AAug 13, 2020

Key People

Founding team and executive leadership

Ivan Cheung

CEO Member Of Board Of Directors

Executive Team

NextPoint Therapeutics Investors

Notable investors and investment history

NextPoint Therapeutics investors
InvestorRounds
MPM CapitalVC Round
Sixty Degree CapitalSeries B Extension, Series B
Binney Street CapitalSeries A, VC Round, Series B Extension, Series B
MPM BioImpactSeries B, Series A, Series B Extension
Catalio Capital ManagementSeries B, Series B Extension
Invus OpportunitiesSeries B Extension, Series B
Arkin Bio CapitalSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2025

    Presenting preclinical data at the AACR Annual Meeting 2025.

  • Apr 7, 2025

    Pioneering preclinical data on NPX125 to be presented.

NextPoint Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NextPoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NextPoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range35
Year Founded2020
Last FundingFeb 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.